{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:12:46Z","timestamp":1793686366947,"version":"4.5.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Inflammation and neurohormonal activation play a significant role in the adverse outcome seen in acute myocardial infarction (AMI) and the development of cardiogenic shock (CS), which is associated with a mortality rate up to 50%. Treatment with anti-inflammatory drugs such as tocilizumab, an interleukin-6 receptor antagonist, has been shown to reduce troponin release and reduce the myocardial infarct size in AMI patients and it may therefore have cardioprotective properties.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a double-blind, placebo-controlled, single-center randomized clinical trial, including adult AMI patients without CS at hospital arrival, undergoing percutaneous coronary intervention (PCI) within 24\u00a0h from symptom onset, and at intermediate to high risk of developing CS (ORBI risk score\u2009\u2265\u200910). A total of 100 participants will be randomized to receive a single intravenous dose of tocilizumab (280\u00a0mg) or placebo (normal saline). The primary outcome is peak plasma pro-B-type natriuretic peptide (proBNP) within 48\u00a0h, assessed using serial measurements at intervals: before infusion, 12, 24, 36, and 48\u00a0h after infusion. Secondary endpoints include the following: (1) cardiac magnetic resonance imaging (CMR) during 24\u201348\u00a0h after admission and at follow-up after 3\u00a0months with assessment of left ventricular area at risk, final infarct size, and the derived salvage index and (2) biochemical markers of inflammation (C-reactive protein and leukocyte counts) and cardiac injury (troponin T and creatinine kinase MB).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Modulation of interleukin-6-mediated inflammation in patients with AMI, treated with acute PCI, and at intermediate to high risk of in-hospital CS may lead to increased hemodynamic stability and reduced left ventricular infarct size, which will be assessed using blood biomarkers with proBNP as the primary outcome and inflammatory markers, troponin T, and CMR with myocardial salvage index as the secondary endpoints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Registered with the Regional Ethics Committee (H-21045751), EudraCT (2021\u2013002028-19), ClinicalTrials.gov (NCT05350592).\u00a0Study registration date: 2022-03-08, Universal Trial Number U1111-1277\u20138523.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-024-08573-0","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:03:30Z","timestamp":1730801010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Joakim Bo","family":"Kunkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Louise Duus","family":"Holle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hassager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Redi","family":"Pecini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille","family":"Palm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Holmvang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia Evi","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Kj\u00e6rgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob Hartvig","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Engstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Eifer","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Thomsen","family":"L\u00f8nborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Frydland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"S\u00f8holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"8573_CR1","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/ejhf.339","volume":"17","author":"L De Luca","year":"2015","unstructured":"De Luca L, Olivari Z, Farina A, Gonzini L, Lucci D, Di Chiara A, et al. Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes: management changes in cardiogenic shock. Eur J Heart Fail. 2015;17:1124\u201332.","journal-title":"Eur J Heart Fail"},{"key":"8573_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ccd.28329","volume":"94","author":"DA Baran","year":"2019","unstructured":"Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Cathet Cardio Intervent. 2019;94:29\u201337.","journal-title":"Cathet Cardio Intervent"},{"key":"8573_CR3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1161\/CIRCULATIONAHA.106.613596","volume":"117","author":"HR Reynolds","year":"2008","unstructured":"Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008;117:686\u201397.","journal-title":"Circulation"},{"key":"8573_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/2048872617706503","volume":"7","author":"L Obling","year":"2018","unstructured":"Obling L, Frydland M, Hansen R, M\u00f8ller-Helgestad OK, Lindholm MG, Holmvang L, et al. Risk factors of late cardiogenic shock and mortality in ST-segment elevation myocardial infarction patients. Eur Heart J Acute Cardiovasc Care. 2018;7:7\u201315.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"8573_CR5","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/eurjpc\/zwaa013","volume":"29","author":"S Montero","year":"2022","unstructured":"Montero S, Bayes-Genis A. The overlooked tsunami of systemic inflammation in post-myocardial infarction cardiogenic shock. Eur J Prev Cardiol. 2022;29:2052\u20134.","journal-title":"Eur J Prev Cardiol"},{"key":"8573_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","volume":"45","author":"MA Matter","year":"2024","unstructured":"Matter MA, Paneni F, Libby P, Frantz S, St\u00e4hli BE, Templin C, et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. Eur Heart J. 2024;45:89\u2013103.","journal-title":"Eur Heart J"},{"key":"8573_CR7","doi-asserted-by":"publisher","first-page":"7639","DOI":"10.1038\/s41598-020-64702-0","volume":"10","author":"J Cuinet","year":"2020","unstructured":"Cuinet J, Garbagnati A, Rusca M, Yerly P, Schneider AG, Kirsch M, et al. Cardiogenic shock elicits acute inflammation, delayed eosinophilia, and depletion of immune cells in most severe cases. Sci Rep. 2020;10:7639.","journal-title":"Sci Rep"},{"key":"8573_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1177\/2048872619896063","volume":"9","author":"M Frydland","year":"2020","unstructured":"Frydland M, M\u00f8ller JE, Lindholm MG, Hansen R, Wiberg S, Lerche Helgestad OK, et al. Biomarkers predictive of late cardiogenic shock development in patients with suspected ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2020;9:557\u201366.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"8573_CR9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/ehjacc\/zuad018","volume":"12","author":"JB Kunkel","year":"2023","unstructured":"Kunkel JB, Josiassen J, Helgestad OKL, Schmidt H, Holmvang L, Jensen LO, et al. Inflammatory response by 48 h after admission and mortality in patients with acute myocardial infarction complicated by cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2023;12:306\u201314.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"8573_CR10","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1161\/CIRCULATIONAHA.120.053318","volume":"143","author":"MAS Meyer","year":"2021","unstructured":"Meyer MAS, Wiberg S, Grand J, Meyer ASP, Obling LER, Frydland M, et al. Treatment effects of interleukin-6 receptor antibodies for modulating the systemic inflammatory response after out-of-hospital cardiac arrest (the IMICA trial): a double-blinded, placebo-controlled, single-center, randomized, clinical trial. Circulation. 2021;143:1841\u201351.","journal-title":"Circulation"},{"key":"8573_CR11","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","volume":"37","author":"O Kleveland","year":"2016","unstructured":"Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016;37:2406\u201313.","journal-title":"Eur Heart J"},{"key":"8573_CR12","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","volume":"77","author":"K Broch","year":"2021","unstructured":"Broch K, Anstensrud AK, Woxholt S, Sharma K, T\u00f8llefsen IM, Bendz B, et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77:1845\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"8573_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1080\/1354750X.2021.1955975","volume":"26","author":"M Th\u00f8gersen","year":"2021","unstructured":"Th\u00f8gersen M, Frydland M, Lerche Helgestad OK, Okkels Jensen L, Josiassen J, Goetze JP, et al. Admission biomarkers among patients with acute myocardial-infarction related cardiogenic shock with or without out-of-hospital cardiac arrest an exploratory study. Biomarkers. 2021;26:632\u20138.","journal-title":"Biomarkers"},{"key":"8573_CR14","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1093\/eurheartj\/ehy127","volume":"39","author":"V Auffret","year":"2018","unstructured":"Auffret V, Cottin Y, Leurent G, Gilard M, Beer J-C, Zabalawi A, et al. Predicting the development of in-hospital cardiogenic shock in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: the ORBI risk score. Eur Heart J. 2018;39:2090\u2013102.","journal-title":"Eur Heart J"},{"key":"8573_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","volume":"40","author":"K Thygesen","year":"2019","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40:237\u201369.","journal-title":"Eur Heart J"},{"key":"8573_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/bmjopen-2020-048312","volume":"11","author":"PD Mark","year":"2021","unstructured":"Mark PD, Frydland M, Helgestad OKL, Holmvang L, M\u00f8ller JE, Johansson PI, et al. Sex-specific mortality prediction by pro-C-type natriuretic peptide measurement in a prospective cohort of patients with ST-elevation myocardial infarction. BMJ Open. 2021;11:11.","journal-title":"BMJ Open."},{"key":"8573_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1515\/CCLM.2010.164","volume":"48","author":"S Buchner","year":"2010","unstructured":"Buchner S, Debl K, Barlage S, Griese D, Fredersdorf S, Jeron A, et al. Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome. Clin Chem Lab Med. 2010;48:875\u201381.","journal-title":"Clin Chem Lab Med"},{"key":"8573_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381.","journal-title":"J Biomed Inform"},{"key":"8573_CR19","doi-asserted-by":"publisher","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners.\u00a0J Biomed Inform. 2019;95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208.","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"8573_CR20","doi-asserted-by":"publisher","first-page":"R1093","DOI":"10.1152\/ajpregu.1984.247.6.R1093","volume":"247","author":"JR Dietz","year":"1984","unstructured":"Dietz JR. Release of natriuretic factor from rat heart-lung preparation by atrial distension. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 1984;247:R1093\u20136.","journal-title":"American Journal of Physiology-Regulatory, Integrative and Comparative Physiology"},{"key":"8573_CR21","doi-asserted-by":"publisher","first-page":"H1572","DOI":"10.1152\/ajpheart.1994.266.4.H1572","volume":"266","author":"M Toth","year":"1994","unstructured":"Toth M, Vuorinen KH, Vuolteenaho O, Hassinen IE, Uusimaa PA, Leppaluoto J, et al. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. American Journal of Physiology-Heart and Circulatory Physiology. 1994;266:H1572\u201380.","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"key":"8573_CR22","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/clc.4960231016","volume":"23","author":"J Tateishi","year":"2000","unstructured":"Tateishi J, Masutani M, Ohyanagi M, Iwasaki T. Transient increase in plasma brain (b-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol. 2000;23:776\u201380.","journal-title":"Clin Cardiol"},{"key":"8573_CR23","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1096\/fj.02-0796fje","volume":"17","author":"JP Goetze","year":"2003","unstructured":"Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Rastrup J, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB j. 2003;17:1105\u20137.","journal-title":"FASEB j"},{"key":"8573_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0002-8703(98)70338-2","volume":"135","author":"N Nagaya","year":"1998","unstructured":"Nagaya N, Nishikimi T, Goto Y, Miyao Y, Kobayashi Y, Morii I, et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J. 1998;135:21\u20138.","journal-title":"Am Heart J"},{"key":"8573_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ahj.2009.11.001","volume":"159","author":"R Jarai","year":"2010","unstructured":"Jarai R, Huber K, Bogaerts K, Droogne W, Ezekowitz J, Granger CB, et al. Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial. Am Heart J. 2010;159:131\u201340.","journal-title":"Am Heart J"},{"key":"8573_CR26","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1093\/eurheartj\/ehac223","volume":"43","author":"S Frantz","year":"2022","unstructured":"Frantz S, Hundertmark MJ, Schulz-Menger J, Bengel FM, Bauersachs J. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J. 2022;43:2549\u201361.","journal-title":"Eur Heart J"},{"key":"8573_CR27","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"The REMAP-CAP Investigators","year":"2021","unstructured":"The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med. 2021;384:1491\u2013502.","journal-title":"N Engl J Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08573-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08573-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08573-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T21:12:06Z","timestamp":1731359526000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08573-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8573"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08573-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The sponsor, the Regional Ethical Committee (H-21045751), and the Danish Medicines Agency (2021073315) have thoroughly examined and approved the protocol along with any modifications, ensuring their scientific integrity and adherence to relevant research and human subject protection standards. Additionally, the Regional Ethical Committee has also reviewed and sanctioned informed consent forms, patient information sheets, recruitment materials, and other required documentation. All participants must provide written informed consent before joining the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"For detailed information regarding consent to participate, please refer to the \"Ethics approval and consent to participate {24}\" section. Similarly, the procedure for obtaining consent can be found in the \"Who will take informed consent? {26a}\" section.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"739"}}